Alternate Careers: Patent Agents and Intellectual Property Attorneys

Posted in Career Advice

Times are tough for many in the legal profession these days. However, the demand for patent experts including attorneys and patent agents is skyrocketing. Openings for patent attorneys account for more than 15 percent of law firm job openings while only 3 percent of lawyers in the US specialize in this area. The bottom line: it is a great time to be a patent attorney or agent in today’s tough economy.

Not surprisingly, many patent attorneys (and agents) usually have a background in science or engineering. And, because of the scarcity of qualified applicants many law firms are doubling their recruiting spending to meet the growing demand for specialists in intellectual property (IP) and patents.

One of the reasons for the growing demand is passage of the America Invents Act, the largest overhaul in theUSpatent system in the past 60 years. The legislation which changes how patents are reviewed and process is spurring competition between firms to higher IP specialist to ease the transition pain. At present, there are over 230 IP openings among more than 1400 lawyer positions nationwide. Many of the openings have been unfilled for over 90 days and more are added daily.

Currently, there are about 40,000 patent attorneys and agents registered with the US Patent and Trademark Office (USPTO). In order to register with the USPTO agents and lawyers are required to pass the patent bar examination. While registered patent agents have taken and passed the exam, they are not lawyers who are required to pass state bar examinations to become licensed attorneys. For those of you who may not know, you don’t have to go to law school to take the patent bar exam nor is a law degree required to take individual state bar exams (however, person who are not law school graduate are likely not to pass the state tests). Patent agents can prepare patents and prosecute cases with the USPTO but cannot litigate in court or draw up contracts. There are roughly 1.2 million licensed patent attorneys in theUSaccording to the American bar association.

The greatest demand for IP attorneys and agents is in information and computing technology and the life sciences. Persons with PhD degrees in the life sciences can sometimes find work at IP and patent law firms. Also, you may be able to find work at a patent examiner with the USPTO! PhD degree holders who have passed the patent bar are even more desirable. However a law degree plus a PhD degree will almost certainly guarantee you employment at most IP firms. That said, before you decide to go to law school, I high recommend that you talk with IP professionals or read a few dozen patent applications (they can all be found at www.uspto.org) in your spare time. If you find the reading interesting or manage to stay awake after reading the fifth application than patent law may be a good choice for you. If not, I suggest that you consider other alternate career options.

Until next time…

Good Luck and Good Job Hunting!!!!!!

 

Bureaucratic Shakeup and More Layoffs at Merck?

Posted in BioBusiness

The Twitterverse was buzzing with activity late last week about a possible shakeup at Merck as Roger Perlmutter takes control as its new head of R&D.  As many of you may know, Perlmutter used to work at Merck but left to become Amgen’s Executive VP of R&D when Peter Kim, the now former Head of Merck’s R&D, was hired several years

Kim’s tenure at Merck was rife with missteps, misdirection and drug approval failures. So, when Amgen replaced its CEO and Merck fired Kim, Perlmutter saw an opportunity to return to the fold with Merck now under the tutelage of CEO Ken Frazier (the man who engineered the company’s Vioxx legal strategy).

Fierce Biotech substantiated the Twitter rumors that a major shakeup may be underway at Merck. According to an article published early on Friday, a Merck spokesperson confirmed that Perlmutter is indeed shaking things up and reorganizing Merck’s R&D infrastructure.

The spokesperson said

“I can confirm that some members of management, but not all Franchise leadership, are leaving the company but are working to ensure a smooth transition.”

The departure of several senior leaders was later confirmed by the Wall Street Journal.  While not confirmed, rumors suggested that Rupert Vessey will lead Merck’s Discovery and Early Development programs.

While Merck spends close to $8 billion annually on R&D, its late stage development pipeline is thin and Perlmutter was hired to strengthen it. Changes at the top usually mean that other changes will take place among the rank and file. That said, stay tuned for possible additional layoffs among Merck R&D personnel.

Until next time….

Good Luck and Good Job Hunting!!!!!!!

LinkedIn and Your Job Search

Posted in Career Advice

While LinkedIn is not considered by many to be a “true” social networking site (some consider it to be little more than a place to post an electronic resume), it is increasingly becoming the place to go to look for or find a job. Most recruiters and many hiring managers used LinkedIn to source qualified candidates for job open at their organizations. That said a well-thought-out and carefully written LinkedIn profile can make the difference between employment or not.

To that end, I came across a great article entitled “Five Minutes to Optimize Your LinkedIn Profile”. Its author, Ian Levine, provide some excellent advice and tips about how to craft a LinkedIn profile so that you will be found by recruiters and prospective hiring managers. Not surprisingly, the key to success is peppering your profile with keywords that are contained in standard job ads in your industry. According to Levine, LinkedIn appears to scan only four categories: Professional Headline, Titles, Specialties and Industries. LinkedIn scans these categories for frequency of the keywords selected.

One way that Levine recommends to assess whether or not your profile is a good one is to enter specific keywords that are consistent with the type of job(s) that you are interested in landing. If your profile comes up at the top (or close to it) of these types of searches than your profile is a good one. A failure to appear in the search results suggests that your profile may need some additional work to land a job!

Until next time…

Good Luck and Good Job Hunting!!!!!!

Some Alternate Career Suggestions

Posted in Career Advice, Uncategorized

Since 2001, 300,000 pharma employees have lost their jobs, primarily in R&D and sales. That’s according to Clifford Mintz, the founder of BioInsights, which develops and offers bioscience education and training. While the losses have been steep, they’re balanced by emerging, in-demand careers in the industry.

The industry’s struggles are well-known: Many companies are facing loss of exclusivity on their biggest sellers but have little in the pipeline to pick up the slack. Productivity is dropping as the cost of bringing a new drug to market soars. Government and payors want more effective drugs for less money. The list goes on.

Developers are looking to new markets and new technologies to address these issues. But how do these trends play out for the pharma job seeker? Many people, particularly Ph.D.s, may have to consider getting additional training if they want to land their dream job. “Companies used to be willing to just hire smart people. But with the economic downturn and global competition, companies can no longer afford to invest in people who have promise. They need to see proven skills,” Mintz explained. With the right blend of skills and experience, however, there still some pharma jobs that are in demand.

Clinical Research and Regulatory Affairs

“Clinical research is the lifeblood of the industry,” Mintz said. As developers expand in emerging markets, there’s a particular demand for people to manage and organize overseas clinical trials. “There’s a huge need for clinical research professionals worldwide,” he said, noting that most Phase I and II trials are conducted outside of theU.S.

Another one of the industry’s perennial needs is regulatory affairs professionals. “Regulatory affairs experience is a skill that all companies large and small would die to get their hands on,” explained Mintz. The increasingly complex and uncertain world of FDA regulation–particularly when it comes to new technology and science–means that companies are always on the prowl for individuals with solid regulatory knowledge and ability to interact with the FDA. You can read more about the demand for clinical research and regulatory affairs jobs here.

Biomanufacturing

The pharma industry’s interest in biologics remains strong–just look at Sanofi’s buyout of Genzyme, or Roche’s purchase of Genentech. They’re lured by disease-altering biologics that are less likely to face generic competition than traditional drugs. As a result, there’s been increased demand for professionals who can navigate the complex world of biomanufacturing. Those with a background in upstream and downstream processes, large-scale protein purification, fermentation technology and bioengineering can make the transition to biomanufacturing.

Healthcare Information Technology

The rise of bioinformatics and genomics coupled with the push for electronic medical records has created jobs in healthcare information technology. Health informatics–the intersection of healthcare and IT–is ideal for people with expertise in genomics, bioinformatics or software that understand how to work with and manipulate large data sets and databases. The Obama administration has made EHRs a priority, and there’s a need for software engineers and biologists who are comfortable working with medical information.

Medical Devices

“The medical devices industry has been experiencing explosive growth for the past decade,” Mintz said. Regulatory hurdles in the medical device industry are much lower than they are for biologics or small molecules, making the industry a more stable alternative to biotech and pharma. The demand for devices, which address problems that can’t be treated with medicine, will continue to grow as the population ages. Job seekers with strong backgrounds in bioinformatics, genomics, engineering and translational medicine are best suited to this field.

Medical Communications

Medical communications–which includes medical writing, editing, graphic design and science journalism–continues to boom. The demand for these jobs has risen because companies need a slew of communication materials to send to patients, physicians, researchers, investigators and the general public about their products and business.

Patent Law and Technology Transfer

Recent changes toU.S.patent laws have increased the demand for patent agents and patent attorneys in the life sciences field. Pharma’s growing reliance on basic research from learning institutions means that there’s a need for technology transfer experts. These experts manage the patent estate and intellectual property of universities and colleges that may engage in licensing deals with the industry. A law degree is a must to compete in this field.

Until next time…

Good Luck and Good Job Hunting!!!!!!

Live From Shanghai, China: The 1st Sino-British Cell Death and Disease Symposium

Posted in BioEducation

Recent progress in cell death, stem cell biology and cancer research has created a new paradigm of research direction, shifting from pure analytical approaches toward a more translational one with animals and patients. The purpose of The 1st Cell Death and Disease Symposium to be held in Shanghai,China onMay 8-9 2013 is to create a forum for the interaction among scientists from China and other parts of the world. It will also provide a platform for development of collaboration.

This year’s symposium is the 4th installment of a series of Sino-British workshops and symposia on cell death. Presenters include scientists from China, England and Australia. Unlike previous conferences, this one will stream live on the Internet for those who are interested in real time viewing.  Vcasts of the symposium will also be available upon conclusion of the event.  For more information about the conference, presenters and agenda please click here

Live streaming in China is still very much in its formative stage. Therefore, those of you who are interested in paid access to a live video stream for the meeting or paid access to vcasts, please contact me via .  Please indicate in the subject line of the message if you are interested in the live stream or the vcasts.

Please note that registering for the conference online does not grant access to live or archived vcasts. This is a special feature offered by BioInsights, Inc in association with the conference organizers.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!

AbbVie to Fire Hundreds of Sales Reps

Posted in BioBusiness

AbbVie, the prescription drug spinoff of Abbott Laboratories revealed that it will be laying off several hundred cardiovascular sales reps. The fired workers will be a mix of full time sales personnel and contract workers.  The reason: generic encroachment of its cardiovascular drug franchises. Among those drugs is TriCor, which began facing generic competition in November. TriCor, along with related medication Trilipix, generated $1.1 billion in U.S. sales for AbbVie last year.. Niaspan, an extended-release version of a medicine to raise HDL also will face generic competition this year It sold $911 million for AbbVie in 2012

AbbVie is shifting its focus from primary care, such as drugs that treat a patient’s cholesterol, stroke or diabetes, to so-called specialty medications in areas of unmet health needs

AbbVie is jumping on the elimination of sales personnel bandwagon and joins Eli Lilly which late last week announced that it plans to dismiss hundreds of sales reps tomorrow, a spokesman confirms. The cuts may amount to 30 percent of the companywide sales force in its BioMedicines division, which includes the cardiovascular, neuroscience and Men’s health units Likewise, last Fall, NJ-based Bristol-Myers Squibb layed off 480 sales reps.

Based on the events of the past five years, it may not be a good idea to pursue a career as   a PhD-trained life scientist or a pharma sales rep!  Surprisingly, however, there is a growing need for biopharmaceutical/biotechnology sales reps….go figure!

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!

The Beat Goes On: More Layoffs at Life Science Companies

Posted in BioBusiness

Despite assurances that the economy is improving, many life sciences companies are still continuing to downsize.  According to the Pharmalot Blog New Jersey-based Mylan (a generic drug manufacturer)  is laying off nearly 120 people from its specialty offices in Basking Ridge, New Jersey, as part of a reorganization that will consolidate the specialty operation near its Pittsburgh headquarters. The cuts were disclosed in a state filing. A spokeswoman says some employees may relocate. The company is also closing a specialty pharmaceutical plant in Napa, California, later this year which will result in the lost of 270 additional jobs.

Likewise, Massachusetts-based Alkermes  plans to eliminate up to 130 jobs from a plant in Ireland  and, last week, Bristol-Myers Squibb (BMY) revealed that roughly 300 employees will lose their jobs as part of a plan to close the San Diego headquarters occupied by Amylin Pharmaceuticals, which was acquired by BMS last year.

Today, another New Jersey company Unigene that is investigating delivery of proteins and peptide-based drugs announced that it would cut up to 40%of it workforce as it reorganizes and tries to stay in business.

Finally, Swiss pharmaceutical giant Novartis said Tuesday it is consolidating its U.S.-based eye disease research projects in Cambridge, Mass., and closing the Novartis Institutes for BioMedical Research group on its Alcon Labs campus in Fort Worth. About 120 employees in Fort Worth were told Tuesday their jobs will end June 11, The employees will be allowed to apply for jobs in Cambridge as well as for other positions with Alcon. Novartis acquired Alcon, an ophthalmic drug company in 2011 and has been working for the past few years to consolidate all of Novartis’ eye research centers in one location in Fort Worth.  Alcon currently employees about 4,800 people.

While these layoffs are noteworthy, the size of these layoffs pale in comparison to the carnage that took place in the pharmaceutical industry over the past five years. According to Challenger Gray & Christmas, the recruiting and consulting firm more only 3,100 pharmaceutical employees lost their jobs this year. However, Ed Silverman, who writes the Pharmalot Blog mentioned in a post today that “there is industry speculation that Merck will undergo more job cuts.”

Although the industry is still shedding jobs, it is likely that the worst is over and that new job opportunities will emerge in the US and elsewhere over time.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

Finding A Recruiter Who Is Right For You!

Posted in Career Advice

I am frequently asked by life sciences job seekers about the value of using a recruiter to aid in a job search.  Generally speaking, experienced life sciences job seekers (those with prior industrial experience) are the only individuals who may benefit from working with a recruiter on a job search.  In reality, recruiters tend not to work with more junior job seekers (e.g., graduate students or postdocs) because they lack prior industrial experience and a majority of the searches conducted on behalf of their clients specify that prior experience is an absolute requirement!

Before you begin the exercise of identifying a recruiter you may want to work with, it is important to understand a bit about the recruiting business works.  First, there are two kinds of recruiters–retained or contingency– and both are paid by the  hiring company not the job candidate.  Retained recruiters are paid an upfront fee (retainer) and a hiring fee whereas contingency recruiters are paid ONLY when their candidate is hired.  While hiring fees can vary widely, they are usually 15% to 30% of a candidates total compensation package.  However, in many cases, the hiring fee is a percentage of a candidates base salary rather than the total compensation package (which can include sign on bonuses and other cash incentives).

When searching for a recruiter, the best approach is to get a referral from a friend or colleague or to search Google or LinkedIn for recruitment firms or recruiters.  If you have heard a recruiter’s name mentioned before or read about them in industry publications that is a good sign that he/she is good at what they do and probably can yield positive results. Once you have identified several prospective recruiter candidates, it is a good idea to read their LinkedIn profile (they will all have one) or Google their names to see what has been written or said about them before making a final decision.

In my experience (as a recruiter and job candidate), it is best to work with only one or two recruiters at a time.  If you work with too many recruiters, your CV will be plastered all over the Internet and probably find its way (in duplicate, triplicate etc) onto the desks of every hiring manager in the life sciences industry. When different recruiters submit the CVs of the same candidate, it signals to prospective hiring managers that the job candidate is desperate for a job, over-exposed, under qualified and certainly not worth hiring.

After identifying a recruiter, send your CV along with an introductory note specifying the type of job that you are looking for, the reason(s) why you are looking for a job, whether or not you are willing to relocate and your compensation requirement.  If the recruiter is willing to work with you, he/she will get back in touch with you via the phone to conduct an interview to get to know you.  It is important to be as honest and as upfront with a recruiter as possible regarding your job requirements and professional and personal circumstances.  This information is confidential and it will enable the recruiter to identify job opportunities that may be right for you.  Withholding information will hinder a job search and also may interfere with job offers.

In many instances, recruiters will contact potential job candidates directly either through referrals from colleagues and friends or via your visibility in your field of study.  Ways to improve visibility include: 1) Articles in trade publications; 2)blogs;  3) activity on social media platforms including LInkedIn and Twitter; 4) Attending industry conferences and 5) Giving seminars and participating on panel discussions.

Finally, it is important to establish some ground rules with the recruiter you decide to work with. First, insist on confidentiality.  If a recruiter cannot guarantee this then it is not a good idea to work with them.  Second, demand that the recruiter contact you with each opportunity that he/she finds for you before they officially submit your name and CV to prospective hiring managers.  In other words, they must get you permission before they submit your name as a job candidate. Also, it is a good idea to tell the recruiter not to post your CV to job boards like Monster, Career Builder, SimplyHired etc. This allows you maintain control over your job search and to ensure that you are not over exposed.

Third, it is important to remember that most recruiters are contingency recruiters and because of this, there is a tendency to show your CV to as many hiring managers as possible so that the likelihood of successfully placing a candidate (and get paid for it) increases.

Fourth, good recruiters will initially ask for a copy of your CV to insure that it is properly formatted and constructed in the best way possible to showcase your talents and strengths. In many cases, recruiters will ask you to rewrite or modify the CV to maximize your candidacy for particular job opportunities. In my experience, recruiters who ask for you CV and provide little or no feedback are likely to be the type of recruiter that simply passes your CV  to as many hiring managers as possible with the hope that it may “stick” somewhere. I highly recommend not working with this type of recruiter.

Fifth, it is important to remember that recruiters are not miracle workers. It is true that they may have contacts at certain companies or have long standing relationships with others but at the end of the day it is really about what strengths, talents and skills that job candidates bring to the table.

Finally, working with recruiters is a good way to learn how to build relationships and it can help to expand your professional network and make connections. It is not uncommon for recruiters to contact persons that they have worked with in the past (successfully or unsuccessfully) for recommendations for a particular position that they are working on. And, if that job is one that you may be interested in, you can always tell them that you want to be considered for the opportunity!

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

 

The Biotechnology Job Market: The Good, the Bad and the Ugly

Posted in BioBusiness

Regeneron Pharmaceuticals, a Tarrytown, NY-based biotechnology company, today announced plans to add 400 new employees to its fast-growing staff upon completion of two new buildings; additional laboratories and office space.  Regeneron, founded 24 years ago, recently hit its stride after receiving regulatory approval for its first big product called Eylea —a treatment for wet age-related macular degeneration—which generated $825 million in sales revenue this past year. This past August, the company received FDA approval for Zaltrap; a colorectal cancer drug that was co-developed with Sanofi.  Finally, the company has a cholesterol-lowering monoclonal antibody drug in Phase III clinical development.  Over the past six years, the headcount at Regeneron has grown from 682 to over 2,000 and the company is still hiring!

Bristol-Myers Squibb (BMS), which eight months ago purchased San Diego-based Amylin Pharmaceuticals for $5.3 billion for it diabetes drug franchise, announced today that it will close Amylin’s corporate headquarters in La Jolla at the end of next year. Employees will be given the option to transfer to other BMS locations. Those who don’t transfer will lose their jobs. At present, 420 people work at Amylin’s corporate headquarters and hundreds will likely be layed off. Before the acquisition, Amylin employed about 1,250 workers. Roughly 300 employees at an Ohio manufacturing site and about 400 sales persons have been absorbed into the BMS workforce. To date, approximately 400 Amylin employees have lost their jobs.

Three weeks ago, pharmaceutical giant Astra Zeneca announced that it was cutting 1,600 R&D jobs by 2016.  Two days later, the company announced that it would cut 2,300 additional jobs (mainly sales and administrative jobs). This brings the layoffs that the company has announced in the last 15 months to 5,050. Since 2007, the company has eliminated over 32,000 jobs.  While this may sound draconian, it is not: most of Astra Zeneca’s competitors including Merck, Pfizer, Novartis, and Bayer etc. have  layed off just as many employees during the same period.  In fact, since 2001 the pharmaceutical industry has shed well over 300,000 jobs.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!!

 

 

 

 

FDA and Social Media: Much Ado About Nothing

Posted in Social Media, Uncategorized

Since the inception of blogs, Facebook, Twitter, YouTube and other social media platforms, many life sciences companies, mainly big pharma, have been anxiously awaiting regulatory guidance from the US Food and Drug Administration on how to use them. Interestingly, FDA did issue some guidance in 2012 on it use last year but many drugmakers felt that it was insufficient and not detailed enough.  Despite the lack of clearly defined regulatory guidance, many companies took the social media plunge anyway. And according to a recent survey of regulatory actions and letters conducted by Mark Senak author of the fabulous EyeonFDA Blog the agency has done very little to thwart the social media strategies implemented by drug companies. In fact, there has been no obvious increase in the number of warning letters or violation letters regarding the use of digital or social media as compared with traditional media violations.

Senak drew this conclusion after analyzing 173 warning and notice of violation letters (advertising and media related) that were issued by the agency from 2008 to 2012.  Of the 173 regulatory letters that were issued, 675 violations were cited and only 43% involved digital media.  And, for the most part, most of the cited violation had little to do with the digital or social media vehicle used but more to do with the message being delivered. For the full report click here.

What does this all mean? While it is difficult to draw any firm conclusion, I believe that the bottom line is that the importance and significant of the long awaited FDA guidance on the use of social media has been overstated. Put simply, if you follow the existing rules guiding advertising and print media, companies ought to be able to craft a regulatory-compliant social media communication strategy without the fear of running afoul of the agency.  Those who violate the existing rules will likely be caught and have to clean up their acts.

The bottom line. Many drug companies have been able to mount very effective social media campaigns without getting into trouble with FDA.  The key to success is following the rules and implementing a digital/social media campaign that has passed internal regulatory muster to insure that everything is in order and regulatory compliant. Companies that have made the investment into digital/social media will be successful whereas others that jump into the game without taking the time to understand the rules of engagement will fail.

Until next time…

Good Luck and Good Job Hunting!!!!